Dy-G (dyphylline / guaifenesin) Disease Interactions
There are 4 disease interactions with Dy-G (dyphylline / guaifenesin):
Dyphylline (Includes Dy-G) ↔ Renal Dysfunction
Severe Potential Hazard, High plausibility
Applies to: Renal Dysfunction
Dyphylline is eliminated almost entirely by the kidney. Drug accumulation may occur in patients with impaired renal function. Like other methylxanthines, high plasma levels of the drug may be associated with severe cardio- and neurotoxicity, sometimes without any previous warning. Therapy with dyphylline should be administered cautiously in patients with renal impairment. Dosage adjustments may be necessary. The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.
References
- "Multum Information Services, Inc. Expert Review Panel"
- "Product Information. Lufyllin (dyphylline)" Wallace Laboratories, Cranbury, NJ.
Methylxanthines (Includes Dy-G) ↔ Pud
Severe Potential Hazard, High plausibility
Applies to: Peptic Ulcer
Methylxanthines are known to stimulate peptic acid secretion. Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease. Some manufacturers consider their use to be contraindicated under such circumstance.
References
- "Product Information. Theo-Dur (theophylline)." Schering Laboratories, Kenilworth, NJ.
- Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996): 1473
- Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985): 328-9
Dyphylline (Includes Dy-G) ↔ Cardiotoxicity
Moderate Potential Hazard, Moderate plausibility
Applies to: Tachyarrhythmia, Angina Pectoris, Myocardial Infarction, Post MI Syndrome, Hyperthyroidism, Hypertension
Like other methylxanthines, dyphylline at high dosages may be associated with positive inotropic and chronotropic effects on the heart. Therapy with dyphylline and products containing dyphylline should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or recent myocardial infarction. The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.
References
- "Multum Information Services, Inc. Expert Review Panel"
- "Product Information. Lufyllin (dyphylline)" Wallace Laboratories, Cranbury, NJ.
Methylxanthines (Includes Dy-G) ↔ Gerd
Moderate Potential Hazard, High plausibility
Applies to: Gastroesophageal Reflux Disease
Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus. Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.
References
- American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
- Stoller JL "Oesophageal ulceration and theophylline." Lancet 2 (1985): 328-9
- Alterman P, Spiegel D, Feldman J, Yaretzky A "Histamine h2-receptor antagonists and chronic theophylline toxicity." Am Fam Physician 54 (1996): 1473
Dy-G (dyphylline / guaifenesin) drug Interactions
There are 122 drug interactions with Dy-G (dyphylline / guaifenesin)
Dy-G (dyphylline / guaifenesin) alcohol/food Interactions
There is 1 alcohol/food interaction with Dy-G (dyphylline / guaifenesin)
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
